Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2023 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, Aug 5, 2022
Slide 1: Cover letter: Press Release and Analyst Presentation on Q1FY23 Results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.afkemlabs.com • CIN: L00305MH1973PLC174201 05 th August, 2022 The Corp
Slide 2: Alkem reports Q1FY23 results
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.co m • CIN: L00305MH1973PLC174201 Press Release Alkem repor
Slide 3: Operational Highlights
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.co m • CIN: L00305MH1973PLC174201 Operational Highlights Do
Slide 4: R&D Investments
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.co m • CIN: L00305MH1973PLC174201 R&D Investments During th
Slide 5: Q1FY23 Conference Call details
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.co m • CIN: L00305MH1973PLC174201 Q1FY23 Conference Call at
Slide 6: Investor Presentation Q1FY23
<a> ALKEM Investor Presentation Q1FY23 August 5, 2022
Slide 7: Safe Harbor Statement
Safe Harbor Statement <a> ALKEM This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of Q1FY23
Key Highlights of Q1FY23 <a> ALKEM • Revenue from Operations declined by 5.7% YoY during the quarter, with EBITDA margin of 7.9% and Net Profit decline of 72.7% YoY • India Business: Company’s secondary sales remained flat compared to IPM decline of 1.8% YoY (Source: IQVIA data) • Market beating per
Slide 9: Key Financial Highlights – Q1FY23 (Consolidated)
Key Financial Highlights – Q1FY23 (Consolidated) <8> ALKEM All figures in ₹ mn Revenue from Operations India sales 19,097 17,815 27,314 25,764 Q1FY22 Q1FY23 International sales 7,903 7,604 Q1FY22 Q1FY23 Q1FY22 Q1FY23
Slide 10: Key Financial Highlights – Q1FY23 (Consolidated)
<a>- Key Financial Highlights – Q1FY23 (Consolidated) ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,366 14,810 5,929 2,032 59.9% ] 57.5% 21.7% 7.9% Q1FY22 Q1FY23 Q1FY22 Q1FY23 PBT (before Minority Interest) PAT (after Minority Interest) 4,681 5,561 1,519 1,276 Q
Slide 11: India Business
India Business <a> ALKEM India Business: Q1FY23 Sales of ₹ 17,815 million (6.7% YoY decline) • India sales contributed 70.1% to total sales in Q1FY23 • In Q1FY23, the Company’s secondary sales remained flat compared to IPM decline of 1.8% YoY (Source: IQVIA data) • Outperformance was mainly led by a
Slide 12: Secondary Sales Performance
Secondary Sales Performance Market beating performance across major therapeutic segments in Q1FY23 +1 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 19.3% 12.9% 10.0% 10.1% -7.8% -12.4% -12.7% - -17.9% Alkem sales growth YoY1,2 +
Slide 13: US Business
US Business <a> ALKEM US Business: Q1FY23 Sales of ₹ 5,565 million (YoY decline of 7.9%) • US sales contributed 21.9% to total sales in Q1FY23 • During the quarter, the US business registered sequential growth of 2.7% over Q4FY22 • In Q1FY23, the Company filed 3 ANDAs with the US FDA and received 4
Slide 14: US Business: Update on US FDA inspections
<a> US Business ALKEM Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 1 observation. The Company has already submitted a detailed Indore Formulations July 2022 response to the US FDA on the corrective and preventive actions it is taking to addres
Slide 15: Other International Business
Other International Business <a> ALKEM Other International Business: Q1FY23 Sales of ₹ 2,039 million (9.6% YoY growth) • Other International Market sales contributed 8.0% to total sales in Q1FY23 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key ma
Slide 16: Latest Shareholding Pattern
<a> Latest Shareholding Pattern ALKEM Shareholding pattern as on June 30, 2022 Non-Institution, 23.09% Promoter & Promoter Group, 57.14% Institution, 19.77% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, O
Slide 17: Thank You
<a> ALKEM Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com